- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02376972
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis (VARIANT)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis
Study Overview
Status
Conditions
Detailed Description
THIS IS A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626 SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS.
PRIMARY ENDPOINT:
TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
SECONDARY ENDPOINT:
TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 191012-1192
- College of Medicine Drexel University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Clinical diagnosis of bacterial vaginosis with Amsel's criteria (4 out of 4 fulfilled criteria):
- Off white (milky or gray), thin, homogeneous, adherent vaginal discharge
- pH >4.5
- Positive "whiff test"
- Presence of clue cells ≥20%
- Bacteriological diagnosis of bacterial vaginosis with Gram stain Nugent score ≥ 4 (patients may be enrolled/randomized without this result)
- Post-menarchal, pre-menopausal female patient
- Non-pregnant (negative urine pregnancy test at Entry Visit/V1) nor breast-feeding patient
- Patient aged between 18 50 years, inclusively
- Patient who is willing to be asked questions about personal medical health and sexual history
- Patient capable of and willing to conform to the study protocol
- Patient who have been thoroughly informed of the aim of the study and the study procedures and who provided signed and dated written informed consent form
- Patient who agrees to abstain from intercourse during the 5 day treatment period
- Patient who agrees also to abstain from intercourse 3 days before the scheduled visits of follow-up
- Patient who agrees to abstain from the use of any other intravaginal product (i.e., douching, feminine deodorants sprays, tampons, spermicides, gels, foams, vaginal birth control ring and diaphragms) during the entire study period
- Patient who agrees to use an adequate method of birth control for the duration of the study to avoid pregnancy. Acceptable methods include a history of bilateral tubal ligation, male partner with a vasectomy, a hormonal contraceptive [oral, patch, injectable or implantable (excluding intrauterine implantable devices [IUD], intrauterine system [IUS] and vaginal rings), or abstinence
- Patient who agrees to abstain from alcohol ingestion during the 5-day treatment period and for 1 day afterward
Exclusion Criteria:
- Virginity
- Patient with other infectious causes of vulvovaginitis (e.g., candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, active Herpes simplex lesions, or Human Papilloma Virus lesions); patients may be enrolled/randomized without these results)
- Other vulvovaginal or cervical conditions, abnormalities or disorders confounding the interpretation of clinical response (including total hysterectomy)
- Symptoms suggestive of pelvic inflammatory disease
- Patient with intra uterine device (IUD), intrauterine system (IUS), or vaginal ring as contraceptive method
- Patient with severe hepatic insufficiency (Child C)
- Patient with severe cardiac insufficiency (NYHA - New York Heart Association classes 3 - 4)
- Patient who will be being evaluated, including colposcopy and cervical biopsies, or being treated during the study period, for abnormal Pap test or cervical carcinoma. To note that if the Pap test will be performed at baseline, the result will be known after the randomization visit: patients may be enrolled without this result
- Any condition or circumstance that would prevent completion of the study or interfere with analysis of study results, including a history of drug or alcohol abuse, mental illness or non-compliance with treatments or visits, immunological (including HIV infection), hematological or neoplastic disease (including all cervical neoplastic diseases)
- Cervical cryotherapy, loop electrosurgical excision (LEEP), cervical laser, or any other ablative or excisional cervical procedures within the last 3 months
- Vaginal laser within the last 3 months
- Patient with clinically relevant pathological laboratory values
- Known hypersensitivity to rifaximin
- Known hypersensitivity to excipients present in rifaximin, placebo or metronidazole formulations
- Known hypersensitivity to metronidazole, either orally or topically administered, or any forms of parabens
- Concurrent anticoagulant therapy with coumadin or warfarin
- Menstruating or anticipated menstruation/withdrawal bleed at Entry Visit/V1 and during the drug administration
- Patient who received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days of randomization
- Patient who have participated in another clinical trial or have taken an investigational drug within the last 4 weeks prior screening
- Patient who has taken disulfuram within the last 14 days
- Withdrawal of informed consent
- Patient previously randomized in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RIFAXIMIN VAGINAL TABLET 25 MG
RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
|
RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
|
Experimental: RIFAXIMIN VAGINAL TABLET 100 MG
RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
|
RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
|
Placebo Comparator: PLACEBO VAGINAL TABLET
PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
|
PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
|
Active Comparator: METROGEL VAGINAL
METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
|
METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CLINICAL CURE OF BACTERIAL VAGINOSIS
Time Frame: Day 22-30
|
RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA, I.E.
NORMAL PHYSIOLOGICAL DISCHARGE, NEGATIVE "WHIFF TEST", CLUE CELLS >20%
|
Day 22-30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS
Time Frame: Day 22-30
|
GRAM STAIN NUGENT SCORE <4
|
Day 22-30
|
THERAPEUTIC CURE OF BACTERIAL VAGINOSIS
Time Frame: Day 22-30
|
AMSEL'S CRITERIA AND GRAM STAIN NUGENT (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE <4)
|
Day 22-30
|
MAINTENANCE OF CLINICAL CURE OF BACTERIAL VAGINOSIS
Time Frame: Day 61-70
|
AMSEL'S CRITERIA (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA)
|
Day 61-70
|
MAINTENANCE OF BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS
Time Frame: Day 61-70
|
NUGENT SCORE <4
|
Day 61-70
|
MAINTENANCE OF THERAPEUTIC CURE OF BACTERIAL VAGINOSIS
Time Frame: 60-69 DAYS AFTER THE FIRST DAY OF TREATMENT
|
AMSEL'S CRITERIA AND NUGENT SCORE (MAINTENANCE OF RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE <4)
|
60-69 DAYS AFTER THE FIRST DAY OF TREATMENT
|
NUMBER, INTENSITY AND TYPE OF ADVERSE EVENTS
Time Frame: Up to Day 70
|
The incidence of adverse events to be summarized by body system and MedDRA preferred term.
|
Up to Day 70
|
LOCAL OBJECTIVE TOLERABILITY
Time Frame: Day 22-30
|
Vaginal mucosa status in terms of erythema (score 0 to 3), edema (score 0 to 3), pethechial hemorrhages (absence/presence), ulcers (absence/presence)
|
Day 22-30
|
LOCAL SUBJECTIVE TOLERABILITY
Time Frame: Day 1 to Day 5
|
Grade (from 0 to 4) of vaginal itching, pain and burning
|
Day 1 to Day 5
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Raffaella Tacchi, MD, Alfasigma S.p.A.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RFX-VAG/003/2012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BACTERIAL VAGINOSIS
-
University of Alabama at BirminghamWayne State UniversityCompletedRecurrent Bacterial VaginosisUnited States
-
Zagazig UniversityUnknownBacterial Vaginosis TreatmentEgypt
-
CDA Research Group, Inc.TerminatedBacterial Vaginosis (BV)United States
-
Unity Health TorontoCompleted
-
Zagazig UniversityRecruitingBacterial Vaginosis | Vaginal | MicrobiologyEgypt
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Mount Sinai Hospital, CanadaUnity Health TorontoCompletedPregnant Women Who Test Positive for Bacterial VaginosisCanada
-
Kaiser PermanenteWithdrawnRecurrent Bacterial VaginosisUnited States
-
Universiti Kebangsaan Malaysia Medical CentreNot yet recruitingBacterial Vaginoses
Clinical Trials on RIFAXIMIN VAGINAL TABLET 25 MG
-
Bausch Health Americas, Inc.CompletedLiver CirrhosisUnited States, Russian Federation
-
GlaxoSmithKlineCompletedGastroparesisUnited States, Australia, Belgium, United Kingdom, Canada, Sweden
-
GlaxoSmithKlineCompleted
-
Alfasigma S.p.A.UnknownPapulopustular RosaceaItaly
-
University of North Carolina, Chapel HillBausch Health Americas, Inc.Not yet recruiting
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedHIV-1-infectionUnited States
-
Wake Forest University Health SciencesUniversity of Minnesota; Nationwide Children's Hospital; University of Texas...Not yet recruitingAbdominal Pain | Cystic Fibrosis | Small Bowel DiseaseUnited States
-
Regenex Pharmaceutical, ChinaCompletedInduction of Labor | Cervical RipeningChina